| Document |
Document Title |
|
JP2020114227A |
To provide compositions of industrially useful alcohol, amine, lactone, lactam and acid, linear fatty acid and linear fatty alcohol with the carbon length of 7 to 25, linear alkane and linear α-alkene with the carbon length of 6 to 24, ...
|
|
JP6728208B2 |
wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as...
|
|
JP2020519647A |
The present invention provides a novel heterocyclic compound of the general formula (I) including a novel compound of the formula (Ia), and a pharmaceutical composition containing them. In addition, for use in the treatment and / or prev...
|
|
JP6715772B2 |
processes for the preparation of such compounds and their use as pharmaceuticals.
|
|
JP6707088B2 |
Provided herein are compositions including the crystalline forms of (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl
)-3H-benzo[b]azepine-4-carboxamide (“Compound A”), methods of making the crystalline forms, and met...
|
|
JP2020079261A |
To provide a novel crystalline form of (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl
)-3H-benzo[b]azepine-4-carboxamide, and a composition containing the crystal, for the treatment of Toll-like receptor 8 related dise...
|
|
JP6701649B2 |
To provide an organic electroluminescence device having a high fluorescence quantum yield and excellent luminous efficiency.The organic electroluminescence device includes, in an organic layer, a π-conjugated compound having a structure...
|
|
JP2020514419A |
Benzazepine compounds, conjugates and pharmaceutical compositions for use in the treatment of diseases such as cancer are disclosed herein. The disclosed benzazepine compounds are particularly useful in the treatment of cancer and the mo...
|
|
JP6688436B2 |
The present invention provides novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V1a and V2 antagonisms, for use in the treatment, prevention, and/or diagnosis of a disease selected from the group consistin...
|
|
JP6672792B2 |
A method for selective production of µ-caprolactam, wherein a substance inducible from a biomass resource is used as a material; the reaction process is short; ammonium sulfate is not produced as a by-product; and production of by-produ...
|
|
JP6645974B2 |
The present invention relates to a process for the preparation of amines, comprising the following steps: a. reaction of a (i) carboxylic acid amide of the general formula (I), or (ii) carboxylic acid diamide of the general formula (II),...
|
|
JP6644792B2 |
This invention relates to novel benzazepine sulfonamide compounds of the formula (I), wherein R4 or R5 is -SO2-NR7R8 and R1 to R8 and Y are as defined in the description and in the claims, as well as pharmaceutically acceptable salts the...
|
|
JP2020015686A |
To provide a manufacturing method of high purity and high yield tolvaptan, a salt thereof, or a solvate thereof without using a solvent with large environmental load, and having enhanced operability of a reaction.There is provided a manu...
|
|
JP6610687B2 |
A power supply device, a photochemical reaction device and method in which the power supply device is used, and a lactam production method in which the photochemical reaction method is used, the power supply device being characterized by...
|
|
JP6582056B2 |
wherein (R1)n, ring (A), Y1, Y2, X, R4, L1, L2, and A1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containin...
|
|
JP2019151650A |
To provide compounds for treating viral infections such as hepatitis B, the compounds having allosteric effector properties against hepatitis B virus core protein (Cp) thereby capable of generating defective capsids in viruses.The invent...
|
|
JP6566546B2 |
|
|
JP2019137610A |
To provide a novel compound that has excellent skin permeability with reduced skin irritation and is used for treating and/or preventing a pain.The present invention provides a compound of formula (I) or a pharmaceutically acceptable sal...
|
|
JP6559251B2 |
Methods for producing lactams from oximes by performing a Beckmann rearrangement using a hierarchical porous aluminophosphate catalyst having interconnected microporous and mesoporous networks are provided. Exemplary catalysts include a ...
|
|
JP2019115352A |
To provide a method for preparing ε-caprolactam (caprolactam) from biochemically prepared 6-aminocaproic acid (6-ACA).A method for preparing caprolactam comprises recovering a mixture containing 6-aminocaproic acid from a culture medium...
|
|
JP6544118B2 |
A method for producing zeolite and a method for producing -caprolactam. It is another object of the present invention to provide a method for producing a zeolite which is more excellent from the viewpoint of catalytic activity. The objec...
|
|
JP6535822B2 |
The present disclosure provides crystalline Compound I and crystalline Compound II, pharmaceutical compositions comprising one of said crystalline compounds suitable for intratympanic administration, and methods for treating otic disorde...
|
|
JP2019516700A |
As used herein, methods of using it for the treatment of diseases including small molecule inhibitors of ASH1L activity and small molecules that promote the degradation of ASH1L, as well as acute leukemia, solid tumors, and other disease...
|
|
JP6522339B2 |
The present invention provides novel fluorescent dyes and kits containing the same, which are useful for labeling a wide variety of biomolecules, cells and microorganisms. The present invention also provides various methods of using the ...
|
|
JP6510068B2 |
A compound or a salt thereof represented by Formula (I). An LSD1 inhibitor containing the compound or a salt thereof as an active ingredient. A pharmaceutical composition containing the compound or salt thereof. An antitumor agent contai...
|
|
JP6499225B2 |
The invention relates to a method for preparing caprolactam comprising recovering a mixture containing 6-aminocaproic acid, from a culture medium comprising biomass, and thereafter cyclising the 6-aminocaproic acid in the presence of sup...
|
|
JP2019034943A |
To provide a novel compound useful as a pregenomic RNA capsid formation inhibitor useful for the treatment of hepatitis B virus (HBV) infection and related disease states.The compound is, for example, a compound represented by formula (X...
|
|
JP6475786B2 |
To provide a novel compound which improves luminous efficiency and a device life of an organic light-emitting device.A novel compound is represented by a formula (I) [Ar-Arare each independently H, D, an alkyl group, an aryl group, a het...
|
|
JP2019014716A |
To provide a method for producing a 4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound which has a superior agonistic activity to an arginine vasopressin V2 receptor and is useful as an active ingredient for a pharmaceutical co...
|
|
JP6446099B1 |
To provide a novel compound and an organic electronic device containing the compound. A novel compound represented by the formula (I).(Ar1 to Ar4 are independently H, dehydrogen, substituted / unsubstituted C1 to C20 alkyl groups, substi...
|
|
JP6438514B2 |
Compounds of the formula (I), in which R1, R3, R5, R6, R7, R, X and Y have the meanings indicated in Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumours.
|
|
JP6419083B2 |
Provided is a photochemical reaction device wherein two partitions formed from an optically transparent material are arranged apart from each other between a light source and a reaction liquid, and an optically transparent fluid introduc...
|
|
JP6417419B2 |
Disclosed are compounds of Formula (I): (I). Also disclosed are methods of using such compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowin...
|
|
JP2018168080A |
To provide an amorphous body of tolvaptan having high safety to human bodies and having an improved elution rate.The present invention provides a method for producing amorphized 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino) ben...
|
|
JP2018527379A |
A method for treating a viral infection with a compound of formula (I) and a composition containing the compound is disclosed. [Chemical 1] [Selection diagram] None
|
|
JP6391571B2 |
Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in th...
|
|
JP2018525342A |
Compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (eg, HDAC1, HDAC2, and HDAC3) are provided herein.
|
|
JP6387023B2 |
The present invention relates to: a compound selected from the group consisting of a tricyclic compound having the structure of formula I, a pharmaceutically acceptable salt, an isomer, a solvate and a precursor thereof; and a use thereo...
|
|
JP6382299B2 |
The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine t...
|
|
JP2018123154A |
To provide a thermodynamically stable polymorphic form of ivabradine hydrochloride, and a preparation method thereof.The invention relates to a novel thermodynamically stable and pure crystalline form of ivabradine hydrochloride (ivabrad...
|
|
JP6359971B2 |
Ivabradine hydrochloride Form IV, its pharmaceutical composition, process for its preparation, and its use as therapeutically active ingredient.
|
|
JP2018087185A |
To provide a novel agrochemical, particularly a herbicide.The present invention provides an oxime compound represented by formula (1) [where B is B-1, B-2 or B-3, Q is NORand the like, Ris C-Calkyl and the like, Ris (C-C) alkyl, optional...
|
|
JP6327853B2 |
The present invention relates to a method for preparing caprolactone, comprising converting 5-hydroxymethyl-2-furfuraldehyde by hydrogenation into at least one intermediate compound selected from the group of 2,5-tetrahydrofuran dimethan...
|
|
JP2018076235A |
To provide a method for producing ε-caprolactam at a high reactivity and a high selectivity by a rearrangement reaction of cyclohexanone oxime produced by even using cyclohexylamine as the raw material.A production method of ε-caprolac...
|
|
JP6325449B2 |
The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Hun...
|
|
JP6320413B2 |
A method is described for the production of purified caprolactam, comprising the steps: a) extraction with an organic extraction agent of raw caprolactam, obtained from the Beckmann rearrangement of cyclohexanone oxime, b) separation of ...
|
|
JP6309513B2 |
|
|
JP6285352B2 |
[Problem] To provide a novel compound that is useful as an agent for preventing/treating cancer. [Solution] One aspect of the present invention provides a compound expressed by the chemical formula (1) or a pharmaceutically permissible s...
|
|
JP6281952B2 |
The present invention provides a novel compound having an antiviral activity, in particular, an HIV replication inhibiting activity, as well as a pharmaceutical composition, in particular, an anti-HIV agent. wherein ring A is substituted...
|
|
JP6280506B2 |
An object of the present invention is to provide a method for producing an optically active amino acid in high yield and in a highly enantioselective manner, which method has fewer restrictions on the material that can be used as the sub...
|
